Posted by Michael Wonder on 14 Jan 2020
Lilly expands insulin affordability options with lower-priced versions of Humalog Mix75/25 KwikPen and Humalog Junior KwikPen
14 January 2020 - List price will be 50% less than branded versions.
Eli Lilly today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of Humalog Mix75/25 KwikPen (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog Junior KwikPen (insulin lispro injection 100 units/mL).
Both insulins will have 50% lower list prices compared to the branded versions and will be available by mid April.
